Lymphangioleiomyomatosis — a wolf in sheep’s clothing

Elizabeth P. Henske1 and Francis X. McCormack2

1Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA. 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, The University of Cincinnati, Cincinnati, Ohio, USA.

Lymphangioleiomyomatosis (LAM) is a rare progressive lung disease of women. LAM is caused by mutations in the tuberous sclerosis complex genes, resulting in activation of the mTOR complex 1 signaling network. Over the past 11 years, there has been remarkable progress in the understanding of LAM and rapid translation of this knowledge to an effective therapy. LAM pathogenic mechanisms mirror those of many forms of human cancer, including mutation, metabolic reprogramming, inappropriate growth and survival, metastasis via blood and lymphatic circulation, infiltration/invasion, sex steroid sensitivity, and local and remote tissue destruction. However, the smooth muscle cell that metastasizes, infiltrates, and destroys the lung in LAM arises from an unknown source and has an innocent histological appearance, with little evidence of proliferation. Thus, LAM is as an elegant, monogenic model of neoplasia, defying categorization as either benign or malignant.

Introduction

LAM is a slowly progressive neoplasm that targets the lung, causing cystic destruction and respiratory failure over one to two decades (1–4). LAM occurs in about 3.4–7.8 per million women (5) (although it is likely to be substantially underdiagnosed) and in at least 30% of women with tuberous sclerosis complex (TSC) (6–8). Clinically significant LAM occurs almost exclusively in women, although radiographic evidence of cystic lung disease consistent with LAM and a few biopsy–documented cases of LAM have been reported in men with (9–11) and without (12) TSC. The average age at diagnosis is about 35 years, typically delayed by 3–5 years due to confusion with more common causes of dyspnea, including asthma or chronic obstructive lung disease (13, 14).

LAM manifestations differ in patients with and without TSC and include recurrent pneumothorax, chylothous pleural effusions, and abdominal tumors, including renal angiomyolipomas and lymphangioleiomyomas; it can also be discovered incidentally on abdominal or chest CTs performed for unrelated purposes (Table 1). Lymphatic obstruction can lead to collection of chylous fluid in the pleural, pericardial, or peritoneal spaces or to fistulous lymphatic connections with hollow viscera including the gastrointestinal or genitourinary tracts. Lung function declines at rates that vary between 3% and 15% per year (15–18), accelerated in some patients by hormonal fluxes associated with menstruation, pregnancy, or birth control pill use (19). By 10 years from diagnosis, about 55% of LAM patients experience shortness of breath with daily activities, 20% require supplemental oxygen, and 10% have died (20).

High-resolution CT scanning reveals diffuse, thin-walled cystic changes that may vary from a few scattered cysts to almost complete replacement of the pulmonary parenchyma with coalescent cysts (Figure 1, A–D, and ref. 21). Typical findings on lung biopsy include smooth muscle cell infiltration of lymphatics, airways, vessels, and alveolar septa (22). The invading “LAM cells” are identified by their spindle-shaped or epithelioid morphology, abundant eosinophilic cytoplasm, and low proliferative index. They stain with antibodies to smooth muscle actin and desmin; with HMB-45, an antibody that recognizes an epitope within the protein gp-100 in the melanogenesis pathway (23); and in many cases, with antibodies to estrogen or progesterone receptors (refs. 24–26 and Figure 1E). The smooth muscle cells within the kidney lesions of patients with angiomyolipomas have a nearly identical morphologic appearance and immunohistochemical profile, and primary and immortalized angiomyolipoma cells are often used as surrogates for LAM cells in laboratory studies. LAM cells also express the lymphangiogenic proteins VEGF-C and VEGF-D and abut slit-like spaces coursing through and surrounding LAM nodules (27, 28). These clefts are lined with endothelial cells that stain with antibodies to VEGFR-3, an antibody that recognizes an appropriate growth and survival, metastasis via blood and lymphatic circulation, infiltration/invasion, sex steroid sensitivity, and local and remote tissue destruction. However, the smooth muscle cell that metastasizes, infiltrates, and destroys the lung in LAM arises from an unknown source and has an innocent histological appearance, with little evidence of proliferation. Thus, LAM is as an elegant, monogenic model of neoplasia, defying categorization as either benign or malignant.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2012;122(11):3807–3816. doi:10.1172/JCI58709.
patients with LAM who seek medical evaluation have this less prevalent “sporadic” form of LAM (S-LAM), which is estimated to affect about 10,000 patients worldwide (5). The reason for the paradoxical relationship between prevalence and frequency of clinical presentation in patients with TSC-LAM and S-LAM is not clear, but it is possible that TSC-LAM and S-LAM have different natural histories, or that other health priorities such as cognitive impairment, seizures, or renal failure affect attention to lung disease in TSC-LAM patients.

Our understanding of the genetic basis of LAM was greatly accelerated by the cloning of the tuberous sclerosis genes TSC1 (35) and TSC2 (36), in the 1990s. TSC-causing mutations are widely distributed across these large genes, composed of 23 and 41 exons, respectively. TSC-LAM occurs in women with germline mutations in either TSC1 or TSC2 (37); however, the majority have germline mutations in TSC2. TSC2 mutations are also more prevalent in the TSC population and tend to cause more severe manifestations (38). LAM cells from some women with TSC-LAM exhibit chromosome 16p13 loss of heterozygosity, indicative of inactivation of the wild-type TSC2 allele (39). Therefore, the pathogenesis of TSC-LAM is consistent with the Knudson ‘two-hit’ tumor suppressor gene mechanism (40), as are most other lesions in TSC, including angiomylipomas, rhabdomyomas, and subependymal giant cell astrocytomas (41). Importantly, a recent genetic analysis of angiomylipomas for regions of genomic loss and of activating and inactivating mutations revealed only TSC2 mutations and not mutations in TSC1, RHEB, or other candidate loci, consistent with a necessary and sufficient role for TSC2 mutations in the pathogenesis of the tumor (42).

By definition, women with S-LAM do not have TSC2 germline mutations (43), yet angiomyolipomas and para-aortic lymph nodes from patients with S-LAM have loss of heterozygosity in the TSC2 region of chromosome 16p13 (44), and inactivating somatic TSC2 mutations have been identified in microdissected LAM cells from the lung (45, 46). Consistent with these observations, FISH analyses of circulating LAM cells isolated from the peripheral blood of women with S-LAM have revealed that the majority have loss of heterozygosity in the TSC2 region of chromosome 16p13 (47). These findings strongly suggest a model whereby inactivation of both alleles of TSC2 is the cause of LAM in the majority of both the TSC-associated and sporadic cases.

### Table 1

<table>
<thead>
<tr>
<th>Lesion</th>
<th>TSC-LAM</th>
<th>S-LAM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung cysts</td>
<td>Often mild</td>
<td>Often profuse</td>
</tr>
<tr>
<td>Elevated serum VEGF-D</td>
<td>100%</td>
<td>70%</td>
</tr>
<tr>
<td>Chyloous pleural effusion</td>
<td>10%</td>
<td>30%</td>
</tr>
<tr>
<td>Pneumocyte hyperplasia</td>
<td>12%</td>
<td>0%–1%</td>
</tr>
<tr>
<td>Abdominal lymphangioliomyoma</td>
<td>9%</td>
<td>29%</td>
</tr>
<tr>
<td>Renal angiomyolipoma</td>
<td>93%</td>
<td>32%</td>
</tr>
<tr>
<td>Single</td>
<td>0%</td>
<td>46%</td>
</tr>
<tr>
<td>Bilateral</td>
<td>92%</td>
<td>19%</td>
</tr>
<tr>
<td>Uterine PEComas</td>
<td>100%</td>
<td>70%</td>
</tr>
</tbody>
</table>

TSC-LAM, Tuberous Sclerosis Complex Associated LAM; LAM that occurs in a patient with TSC; S-LAM (Sporadic LAM); LAM that occurs in a patient without TSC.

### TSC gene mutations in LAM cells lead to activation of the TORC1 signaling network

The TSC2 gene encodes tuberin (48), a highly evolutionarily conserved GTPase-activating protein (GAP), and TSC1 encodes hamartin, which heterodimerizes with tuberin (49) and appears to be essential for its function (Figure 2A). Rheb, a Ras homolog, is maintained in an inactive state by tuberin (50, 51). The TSC1/TSC2/Rheb triad constitutes a critical cellular signaling node, serving as a gatekeeper by sensing upstream inputs including growth factor activation, oxygen tension (52), amino acid availability, and ATP levels to regulate the downstream functions of TORC1 (reviewed in refs. 53–55). The direct targets of TORC1 continue to be defined and include P70 S6 kinase and 4EBP1, which regulates protein translation; ULK1, which is a master regulator of autophagy (56–58); and growth factor receptor–bound protein 10 (GRB10), an adaptor protein that contributes to feedback regulation of PI3K signaling (59, 60). Several other feedback loops that regulate mTOR pathway signaling have also been described, many of which have potentially important implications for the response to TORC1-targeted therapies (61).

Studies from many groups have demonstrated that activation of TORC1 in LAM cells and/or other TSC2-deficient cells leads to phosphorylation of ribosomal protein S6, growth factor–independent growth, increased cell size (62), enhanced cell survival, and suppressed autophagy (56, 63). Evidence of dysregulation of this “canonical” TSC/Rheb/TORC1 signaling network has also been consistently observed in tumor cells from animal models of TSC (64–66), in angiomylipomas from women with S-LAM (67, 68), and in LAM cells isolated from explanted lungs of LAM patients (69). Sirolimus, a highly specific inhibitor of TORC1, suppresses growth of spontaneously occurring renal tumors in the Tsc2–/- Eker rat model (65) and in Tsc1–/- and Tsc2–/- mice (70), as well as TSC2-deficient xenograft tumors in immune-deficient mice (56, 70, 71). Based on these preclinical data, trials of sirolimus therapy in humans with tuberous sclerosis or LAM began in 2003.

In addition to the canonical TSC/Rheb/TORC1 pathway, data from a variety of experimental systems have pointed toward the existence of noncanonical functions of TSC1/2 and Rheb (reviewed in ref. 63 and Figure 2B). The molecular mechanisms and clinical significance of these are generally less well understood than the canonical mechanisms, but include aggresome formation (72), regulation of the primary cilium (73, 74), regulation of the cytoskeleton and RhoA via hamartin (75) or TOR complex 2 (TORC2) (71), and regulation of cellular differentiation and proliferation via B-Raf (76, 77) and Notch (63, 78).

### Pathways affecting proliferation and survival of LAM cells: apoptotic susceptibility and links to proliferation stimuli

Resistance to cell death is a critical capability for neoplastic cells. Paradoxically, compelling data indicate that TSC2-deficient cells are more susceptible than their wild-type counterparts to apoptosis triggered by ER stress (72, 79) and glucose deprivation (80, 81). Elevated p53 transcription and translation rates may also contribute to stress-induced apoptosis (82). In contrast, under some circumstances, such as serum deprivation, TSC-deficient cells appear to be resistant to apoptosis. This may be mediated through FKBP38 (83). Regulation of the apoptotic potential of LAM cells is context-dependent and intimately related to met-
Abolic reprogramming and the nature of mitogenic stimuli. A variety of factors are likely to contribute to the proliferation of LAM cells, including β-catenin, which is activated in LAM (84–86), associated with upregulation of cyclin D1 (84), and contributes to LAM cell invasiveness (87); HMGA2, an architectural transcription factor that is misexpressed in a number of mesenchymal neoplasms (88); Polo-like kinase–1 (PLK1) (89) and PLK2 (90), which interact directly with TSC1 in a cell cycle–dependent manner; cyclin-dependent kinase inhibitor p27, which is mislocalized to the cytoplasm in TSC-deficient cells (91, 92); and prolactin, a hormone and smooth muscle mitogen that is elevated in the serum of patients with LAM (93). A better understanding of these apoptotic and proliferative factors could lead to clearly targetable nodes.

**Autophagy-dependent cell survival**

Autophagy can play both pro-survival and pro-death roles during tumor initiation and tumor progression (Figure 2C). TORC1 is a key inhibitor of autophagy via ULK1 (94–99), and markers such as the adaptor protein p62/sequestome 1 (p62/SQSTM1) indicate that autophagy levels are low in TSC-deficient LAM cells (56). Mice that are heterozygous for both TSC2 and Beclin-1 (an autophagy effector) show a decrease in the number of renal cystadenomas compared with mice heterozygous for Tsc2 alone, suggesting that inhibition of autophagy decreases the survival and/or proliferation of TSC2-deficient cells. In addition, treatment with the autophagy inhibitor chloroquine results in a decrease in the size of renal tumors in TSC2-deficient mice (56). Treatment with sirolimus, on the other hand, may promote LAM cell survival by activating autophagy. Consistent with this concept, the combination of sirolimus and chloroquine appears to be particularly effective at inhibiting the growth of TSC2-deficient cells, both in vitro and in vivo (56). Taken together, these data suggest that low levels of autophagy in TSC2-deficient LAM cells serve to limit their growth and survival, and that dependence on autophagy could represent a therapeutically targetable “Achilles heel.” Interestingly, p62/SQSTM1, which accumulates in cells with defective autophagy, may enhance the tumorigenic potential of TSC2-deficient cells (100). p62/SQSTM1 also activates Nfr2 and NF-κB and may thereby mediate the production of pro-survival cytokines that allow LAM cells to resist cell death (101–103).
Estrogen-induced effects on cell survival and proliferation

One of the leading mechanistic hypotheses for the remarkable propensity of LAM to affect females is that estrogen enhances the neoplastic potential and survival of LAM cells. Estradiol promotes the proliferation of TSC2-deficient cells in rat models of TSC-LAM, both in vitro and in vivo (100, 104, 105) and has been observed to activate non-genomic signaling networks in primary cultures of angiomyolipoma cells ex vivo (106). Recent evidence suggests that estrogen-dependent signaling networks provide one of the central mechanisms by which LAM cells resist apoptosis. In TSC2-deficient cells, estrogen activates MAPK, perhaps in part through production of reactive oxygen species (107), and promotes resistance to anoikis-induced apoptosis through (MAPK-dependent) degradation of Bim (106). Furthermore, estrogen enhances the survival of intravenously injected TSC2-deficient cells and the recovery of circulating TSC2-deficient cells in the plasma of mice bearing xenograft tumors (106).

RhoA and LAM cell survival

TSC2-deficient LAM cells may also evade apoptosis via activation of RhoA (Figure 2B). Goncharova et al. found that downregulation of RhoA in TSC2-deficient rat–derived cells increases apoptosis and upregulates the proapoptotic proteins Bim, Bok, and Puma (71). Interestingly, the RhoA activation appears to be dependent on TORC2, rather than TORC1, and inhibition of RhoA using simvastatin induces apoptosis in vitro. Most importantly, the combination of sirolimus and simvastatin inhibited xenograft tumor growth and completely blocked the recurrence of xenograft tumors after treatment withdrawal (71). This finding may have fundamental translational significance for combinatorial therapeutic strategies to induce the death of LAM cells, potentially obviating the need for continuous, life-long suppressive therapies.

Metabolic reprogramming of LAM cells mimics that seen in cancer

Otto Warburg recognized in 1930 that cancer cells utilize glycolysis rather than oxidative phosphorylation for energy production, even in aerobic conditions, despite the far lower yield of ATP per molecule of glucose (108). This “Warburg effect” has received increasing attention over the last five years as a hallmark feature of most cancer cells and other rapidly dividing cells (109). TORC1 is a master regulator of cellular metabolism through several mechanisms that may allow LAM cells to redirect energy metabolism toward biosynthetic programs. Activation of mTOR in TSC-deficient cells appears to promote the Warburg effect by increasing HIF-1α and sterol regulatory element–binding proteins (SREBP1 and SREBP2) (110) that are involved in glycolysis, the oxidative arm of the pentose phosphate pathway, and lipid biosynthesis (81). Surprisingly, angiomyolipomas (111) and LAM tissues (112) have relatively low fluorodeoxygluose (FDG) uptake on PET scanning, compared with most human neoplasms. Decreased glucose uptake is due in part to defective membrane localization of glucose transporter proteins (Glut1, -2, and -4) (111). TSC1/2-deficient cells are also hypersensitive to glucose deprivation (81). The reliance on glucose is closely linked to a dependence on glutamine metabolism via the TCA cycle, and inhibitors of glutamate dehydrogenase, such as the green tea component epigallocatechin-3-gallate (EGCG), can induce the death of TSC-deficient cells both in vitro (80, 113) and in vivo (114). Furthermore, TSC2-deficient...
cells have recently been found to preferentially express pyruvate kinase M2 (PKM2) (115), which is expressed by most cancer cells and enhances glycolytic flux by slowing the TCA cycle. Agents that selectively inhibit glucose or glutamate uptake or utilization, or that activate PKM2, and thereby target these “metabolic vulnerabilities” could be exploited to induce the death of LAM cells.

Novel mechanisms of invasion, metastasis, and immune evasion facilitate the spread of LAM

Mounting evidence suggests that LAM cells behave in a manner that is reminiscent of low-grade sarcoma cells, based on their smooth muscle features (spindled morphology, and smooth muscle actin and desmin staining) and their neoplastic, metastatic, and destructive potential. Genetic analyses of microdissected LAM lesions in the lungs and kidneys of a few women with sporadic LAM have revealed identical TSC2 mutations in the two locations (43). This discovery led to the paradigm-shifting “benign metastasis” model of LAM pathogenesis, in which LAM cells spread from angiomyolipoma to the lung, or from a peripheral source to both lung and kidney, despite their innocent histological appearance and low proliferative potential (116). Consistent with the benign metastasis model, two independent genetic studies of the cells that constitute recurrent LAM lesions in the donor lung of human LAM patients who had been transplanted demonstrated that they derive from the recipient rather than from the allografts (46, 117).

The source of LAM cells has remained unclear, akin to a cancer of unknown primary. LAM cells express melanocytic antigens, consistent with a potential origin in the neural crest. Other neural crest lineage tissues appear to be impacted in TSC patients, leading to pitting of the dental enamel and hypomelanotic skin lesions (32). The propensity of LAM cells to migrate and metastasize is reminiscent of the highly migratory behavior of neural crest progenitor cells during embryonic development. The uterus is a particularly attractive candidate as a source of these neural crest progenitor cells, and this explanation would make sense of their estrogen receptor expression and responsiveness (118). LAM, angiomyolipomas, and clear cell “sugar” tumors of the lung have been recently classified as perivascular epithelioid cell tumors, or PEComas, mesenchymal tumors composed of histologically and immunohistochemically distinctive cells (with no known normal anatomic counterpart) that express myoid and melanocytic markers. PEComas are most commonly found in the uterus and peritoneum (119–122). A recent study found a very high prevalence of uterine PEComa lesions in patients with S-LAM and TSC-LAM, fueling speculation that uterus may be the “primary tumor” source of LAM cells in many cases (118). Several investigators have proposed that the angiomyolipoma may be a source in
some patients, but only about 30% of women with S-LAM have radiographically detectable angiomylipomas. The thoracic duct is frequently extensively infiltrated with LAM cells at autopsy (22), suggesting that LAM may arise from a site within the lymphatic system (Figure 3). LAM cell clusters in chylous fluid (123, 124) are composed of TSC mutation–bearing smooth muscle actin–positive spindle cells enveloped by lymphatic endothelial cells. Kumasaka et al. have proposed that LAM cells, through their expression of VEGF-C and VEGF-D, drive a lymphangiogenic program that demarcates the LAM cells into endothelium-rimmed islands (27, 28). After budding into the lumen, LAM cell clusters leapfrog up the lymphatic tree through serial cycles of implantation and shedding, and are transported by lymphatic flow to the venous circulation and the pulmonary microvasculature (125). The VEGFR-3–expressing endothelial cells that envelope the LAM cell clusters may serve to shield mutation-bearing LAM cells from immune surveillance against novel or ectopic surface antigens they express, such as the glycolipid GD-3 (126). Long dwell times of these “tumor emboli” in the pulmonary capillaries may facilitate metastasis by a process similar to that proposed for the angiogenesis-driven, “invasion-independent” mechanism described for endothelial cell–lined renal cell carcinoma clusters that gain access to the interstitium via surrounding venules (127, 128).

Cyst formation in the lung

LAM cell infiltration and elaboration of matrix-degrading enzymes likely drive the formation of cysts in the lung and contributes to both the obstructive and restrictive physiologic defects that are characteristic of LAM. Immunohistochemical staining of LAM lesions demonstrates overexpression of MMPs and metalloproteinase inducers, as well as a paucity of the tissue inhibitor of metalloproteinases TIMP-1 (129–131). Although MMP-2 is the most abundantly expressed MMP in LAM tissue, serum levels of MMP-9, but not MMP-2, are elevated in patients (132–134). LAM cells also exhibit strong immunoreactivity for cathepsin K, a protease that is downstream of mTOR in osteoclasts (135). Whether all of the airspace enlargement in LAM is the result of proteases secreted by LAM cells is not entirely clear. The abundance of lymphatic spaces and expression of VEGF-C, VEGF-D, VEGFR-3, Lyve-1, and podoplanin within LAM lung lesions has led to the hypothesis that disorganized lymphangiogenesis may underlie the program of metalloproteinase expression and lung remodeling in LAM (Figure 4). Elucidation of the spatial and temporal expression of proteases during lymphatic development may therefore shed light on the mechanisms of cystic remodeling in LAM and perhaps also lead to therapeutic strategies for targeting these mechanisms.

Clinical trials of sirolimus in LAM

The Cincinnati Angiomyolipoma Sirolimus Trial (CAST) was initiated in 2003 (136). Patients with angiomyolipomas due to either TSC or LAM were treated with escalating doses of sirolimus for one year, followed by one year of observation off therapy. Renal angiomylipoma volume decreased by about 50% on the drug and then increased back to near baseline levels when sirolimus was stopped. Similar results were seen in subsequent trials (137, 138). On the basis of an unexpected lung function response in CAST, and the appreciable rate of adverse events, a pivotal trial was designed to determine the risks and benefits of sirolimus in patients with LAM. The Multi-center International LAM Efficacy of Sirolimus (MILES) trial was a double-blind, randomized, controlled trial of sirolimus in 89 adult females with LAM and abnormal lung function (139). During the treatment period, lung function stabilized with sirolimus treatment,

![Figure 4](https://www.jci.org)  
**Figure 4**  
Mechanisms of airspace enlargement in LAM. Two models of airspace enlargement in LAM are presented; these may not be mutually exclusive. (A) LAM cells secrete proteases including MMPs and cathepsin K, which degrade the extracellular matrix and induce apoptosis of alveolar epithelial cells. (B) LAM cells express lymphangiogenic growth factors, VEGF-C and VEGF-D, recruit lymphatic endothelial cells, drive the formation of lymphatic vascular channels and distort the lung architecture. Original magnification, ×200.
and it declined by about 11% in the placebo group. After discontinuation of sirolimus, lung function decline resumed in the sirolimus group and paralleled that in the placebo group. Serum VEGF-D was markedly reduced by sirolimus, but tended to increase again when the drug was withdrawn. Adverse events were more common with sirolimus, but the frequency of serious adverse events was balanced between the groups. The data suggest that sirolimus therapy may attenuate tumor cell infiltration or proliferation within the lung, but does not result in durable remission. The tumor regression seen in CAST and the other renal trials is instructive in this regard, and suggests that sirolimus therapy may be cytostatic and reduce cell size, but will not lead to apoptosis and cell death in TSC-deficient cells. It is possible that mTOR inhibitors must be given continuously to maintain cellular homeostasis and avoid angiomylipoma regrowth and lung function decline; indeed, there is early evidence of sustained benefit from long-term therapy (137, 140). The decreases in VEGF-D in patients receiving sirolimus (138, 139) are intriguing in light of the strong lymphangiogenic phenotype observed in LAM and marked improvement in chylous effusions and lymphangioleiomyoma volume in LAM patients with lymphatic involvement (140). Finally, the trial utilized a multisite international approach to clinical trial design in LAM, with more than a dozen participating sites in three countries. This investigator-initiated network facilitated the efficient testing of therapeutic strategies in LAM, and may also serve as a model for research on other rare diseases (141).

**The way forward**

Less than 15 years elapsed between the identification of the genetic etiology of LAM and the discovery of an effective therapy. However, additional action is necessary to identify strategies that will benefit women with LAM in the fastest possible time. Better cellular and animal models are needed, and additional biomarkers that predict disease progression and response of LAM to targeted therapies will be critical for future clinical trial design. Earlier diagnosis through screening of populations of women with TSC and women with sporadic LAM who may present with pneumothorax or nonspecific respiratory symptoms (142) is essential to facilitate treatment before irreversible lung damage occurs. Quantitative imaging techniques to measure lung destruction and LAM cell burden are needed, as current pulmonary function testing methods are insensitive, nonspecific, and effort dependent. Finding effective treatments for LAM will also require an iterative "bedside to bench and back to bedside" effort by investigative teams with broad expertise in basic, translational, and clinical science. Emerging preclinical evidence has set the stage for testing of kinase inhibitors, estrogen-targeted therapies, autophagy inhibitors, and lymphangiogenesis inhibitors (Figure 5). Combination strategies based on cancer treatment paradigms that target codependent or redundant cellular pathways to induce the death of LAM cells, with the objective of remission induction rather than disease suppression, are currently being tested in animal models. FDA-approved drugs with well-understood safety profiles are already available for many of the targets under consideration. Fortunately, mechanisms are already in place to rapidly and efficiently test promising therapeutic strategies through the coordinated efforts of an international team of investigators and an organized, motivated LAM patient community.

**Figure 5**

Future directions in therapy for LAM. (A) Potential cell-autonomous therapeutic approaches in LAM include TORC1 inhibitors that may more effectively inhibit TORC1 (including kinase domain inhibitors) and/or have favorable toxicity and/or pharmacokinetic features; autophagy inhibitors; inhibitors of the putative “noncanonical” functions of TSC and Rheb, including Notch activation and Rho activation; direct inhibitors of Rho's activity (such as farnesyl transferase inhibitors). (B) Potential non-cell-autonomous therapeutic targets in LAM include inhibition of the lymphatic recruitment and vascular remodeling via inhibition of VEGF or VEGFR; inhibition of MMPs, cathepsin K, and other proteases that contribute to alveolar destruction; inhibition of LAM cells utilizing melanocyte or neural crest antigens as targets; and estrogen antagonism.
19. Shen A, Iseman MD, Waldron JA, King TE. Exacer-
24. Loggiudino H, Ao X, Russo I, Henske EP. Frequent estrogen and progesterone receptor immunoreac-
25. Auffray CM, et al. Pulmonary lymphangiolei-
26. Matsui K, et al. Downregulation of estrogen and pro-
28. Kumaaka T, et al. Lymphangiogenesis in lymph-
angioleiomyomatosis: its implication in the pro-
29. Young LR, Inoue Y, McCormack FX. Diagnostic pro-
30. Young LR, Inoue Y, McCormack FX. Diagnostic pro-
35. Auffray CM, et al. The National Institute of Diabe-
tes and Digestive and Kidney Diseases (to E.P. Henske), Veteran's Administration (to F.X. McCormack), and The National Heart, Lung and Blood Institute (to E.P. Henske and F.X. McCormack). Address correspondence to: Francis X. McCormack, University of Cincinnati School of Medicine, Division of Pulmonary and Critical Care Medicine, P.O. Box 670564, MSB 6165, 231 Bethesda Avenue, Cincinnati, Ohio 45267-0564, USA. Phone: 513.558.0480; Fax: 513.558.4858; E-mail: frank.mccormack@uc.edu.
112. Young LR, et al. Utility of [18F]2-fluoro-2-deoxy-
glucose-PET in sporadic and tuberous sclerosis-
113. Choo YV, Blenis J. Not all substrates are treated equal-
ly: implications for mTOR, rapamycin-resistance and
114. Yang P, Li H. Epigallocatechin-3-gallate amelio-
rates hyperglycemia-induced embryonic vasculopla-
thy and malformation by inhibition of Foxo3a acti-
115. Sun Q, et al. Mammalian target of rapamycin up-
regulation of pyruvate kinase isoenzyme type M2
116. Henske EP. M etastasis of benign tumor cells in
117. Karbowinicz M, et al. Recurrent lymphangioleio-
myomatosis after transplantation: genetic analyses
118. Hayashi T, et al. Prevalence of uterine and adrenal
involvement in pulmonary lymphangioleiomyo-
120. Hornecker JL, Fletcher CD. PEComa: what do we
know so far? Histopathology. 2006;48(1):75–82.
121. Artnah HB, Parwani AV. Malignant perivascular epithelioid cell tumor (PEComa) of the uterus with
late renal and pulmonary metastases: a case report
with review of the literature. Diagn Pathol. 2007; 2:45.
122. Wagner AJ, et al. Clinical activity of mTOR inhibi-
tion with sirolimus in malignant perivascular epithe-
lioid cell tumors: targeting the pathogenic acti-
123. Valenti OJ. Pulmonary lymphangiomyoma, a probable forme frust of tuberous sclerosis. A case
124. Itami M, Teshima S, Asakuma Y, Chino H, Aoyama
K, Fukushima N. Pulmonary lymphangioleiomyo-
matosis diagnosed by effusion cytology. A case report.
125. Seyama K, Kumasaka T, Kurihara M, Mitani K, Sato
T. Lymphangioleiomyomatosis: a disease involve-
eexpression in lymphangioleiomyomatosis renders
of blood-borne metastasis: a new murine mammary
128. Sugino T, et al. Morphological evidence for an
invasion-independent metastasis pathway exists in
129. Hayashi T, et al. Immunohistochemical study of
matrix metalloproteinases (MMPs) and their tissue
inhibitors (TIMPs) in pulmonary lymphangioleio-
130. Fukuda Y, Ishizaki M, Kudoh S, Kitaichi M, Yamanaka N. Localization of matrix metallopro-
teins-1, -2, and -9 and tissue inhibitor of metallo-
receptor contributes to the progression of pul-
monary lymphangioleiomyomatosis via matrix
metalloproteinase-induced cell invasiveness. J Clin
132. Pimenta SP, Baldi BG, Acencio MM, Kairalla RA,
Carvalho CR. Doxycycline use in patients with
lymphangioleiomyomatosis: safety and efficacy
133. Odajima N, Betsuyaku T, Yoshida T, Hosokawa
T, Nishimura M. High levels of extracellular
matrix metalloproteinase inducer are expressed in
134. Odajima N, Betsuyaku T, Nasuhraya Y, Inoue H,
Seyama K, Nishimura M. Matrix metalloprotein-
135. Chilosi M, et al. Cathepsin-k expression in pul-
monary lymphangioleiomyomatosis. Mod Pathol.
136. Bissler JJ, et al. Sirolimus for angiomyolipoma in
tuberous sclerosis complex or lymphangioleio-
137. Davies DM, et al. Sirolimus therapy for angio-
myolipoma in tuberous sclerosis and sporadic
lymphangioleiomyomatosis: a phase 2 trial. Clin
138. Dabora SL, et al. Multicenter phase 2 trial of siro-
limus for tuberous sclerosis: kidney angiomyolipo-
mas and other tumors regress and VEGF- D levels
139. Mc Cormack FX, et al. Efficacy and safety of siroli-
140. Taveira–DaSilva AM, Hathaway O, Stylianou M,
Moss J. Changes in lung function and chylo-
effusions in patients with lymphangioleiomyo-
141. Gupta S, Bayoumi AM, Faughman ME. Rare lung
disease research: strategies for improving identi-
Fication and recruitment of research participants.
142. Hagaman JT, Schauer DP, McCormack FX, Kinder
BW. Screening for lymphangioleiomyomatosis by
high-resolution computed tomography in young,
nonsmoking women presenting with spontane-